A Randomized, Double-blind, Crossover Study to Assess the Effects of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension

Date de début de l'étude : 1 août 2012

Key Inclusion Criteria: Written informed consent must be obtained before any study assessment is performed. Males and females of non-childbearing potential and of legal age (at least 18 years or older as defined by local law). Asian patients with mild to moderate essential hypertension, untreated or currently taking antihypertensive therapy with up to two drugs. Key Exclusion Criteria: Women of child-bearing potential. History of angioedema, drug-related or otherwise History of hypersensitivity to LCZ696, valsartan, or drugs of similar chemical classes. Severe hypertension (grade 3 of WHO classification; msDBP ≥100 mmHg and/or msSBP ≥ 180 mmHg) at screening or at the end of the washout period. History or evidence of a secondary form of hypertension, Transient ischemic cerebral attack (TIA) during the 12 months prior to screening or any history of stroke. History of myocardial infarction, coronary bypass surgery or percutaneous coronary intervention (PCI) during 12 month prior to screening. Current or history of hypertensive retinopathy. Previous or current diagnosis of heart failure (NYHA Class II-IV). Clinically significant valvular heart disease at screening. Other protocol defined inclusion/exclusion criteria may apply